Back to News
Market Impact: 0.35
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington's Disease
Source: globenewswire.com
Healthcare & BiotechRegulation & Legislation
The FDA set a May 1, 2027 PDUFA target action date for uniQure’s ifezuntirgene inilparvovec. If approved, the treatment would be the world’s first disease-modifying therapy for Huntington’s disease; approval has not yet been granted.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
QURE0.60
More News
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- How Trump’s trade policy is handing Asia to Beijing
- RA Capital Management sells $9.13M in Lenz Therapeutics shares
- Karyopharm stock rating cut to neutral by Rodman on bankruptcy
- Apple may try to increase revenue by doing…something with third-party AI apps